case_images: PMC11803542_01
case_images: Patient's skin condition before, during, and at the end of treatment. (A) Nodular changes in the orbital area before starting treatment (1st clinical consultation); (B) Nodular changes in the orbital area before starting treatment (1st clinical consultation); (C) Nodular changes in the area of nasolabial folds (1st clinical consultation); (D) Intensification of lesions (2nd clinical consultation); (E) Frontal region (2nd clinical consultation); (F) Reduction of erythema around nodules (3rd clinical consultation); (G) Reduction of erythema around nodules (3rd clinical consultation); (H) 4th clinical consultation; (I) 4th clinical consultation; (J) 5th clinical consultation; (K) 5th clinical consultation; (L) Condition 1 year after the start of treatment:last clinical consultation; (M) Frontal region:last clinical consultation.
case_images: JOCD-24-e16792-g003.jpg
case_images: PMC11803542_01_JOCD-24-e16792-g003.jpg
case_images: jocd16792-fig-0001
case_images: The injected nodules reduced in size, and the remaining nodules turned pale and softer (Figure 1F). However, reddened nodules around the eyes were still present but were smaller than those observed during previous clinical consultations (Figure 1G). More than half of the lesions had disappeared (Figure 1H). A single hard nodule with a diameter of 2-3 mm, flesh-colored, and demarcated around the eyes persisted (Figure 1I). Single post-inflammatory hyperpigmentation marks and small atrophic scars were found in the locations of the larger lesions as well as erythematous changes around the periorbital area (Figure 1J,K).